{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.7","upperLimit":"77.8","value":"71.78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"257"}],"units":"Participants"}],"description":"DFS time is defined as time from end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. 5-year DFS will be estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Down Syndrome HR patients receive post-Induction therapy regimen","id":"OG000","title":"DS HR B-ALL"}],"paramType":"NUMBER","populationDescription":"Patients with DS and HR B-ALL treated with modified Induction and post induction therapy with MBFM-IMIDM. Inevaluable patients were excluded from analysis","reportingStatus":"POSTED","timeFrame":"At 5 years","title":"5-year DFS in Patients With Down Syndrome (DS) and HR B-ALL Treated With Modified Induction and Post-Induction Therapy Regimen With MBFM-IMIDM","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}